Study Shows Results for SkylineDx’s Test for Early-Stage Melanoma
By Karen Roman Oncology-focused biotech company SkylineDx said an independent study shows that Merlin CP-GEP, the company’s test for treatment decisions in early-stage melanoma, correctly categorizes patients with skin melanoma for sentinel lymph node biopsy (SLNB). Merlin acts as a...